Stammdaten
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Unternehmen & Branche
| Name | CytoDyn Inc. |
|---|---|
| Ticker | CYDY |
| CIK | 0001175680 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 429,6 Mio. USD |
| Beta | 1,17 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-02-28 | 10-Q | -4,690,000 | 0.00 | 18,497,000 | -104,287,000 | |
| 2025-11-30 | 10-Q | -22,607,000 | -0.02 | 8,935,000 | -119,747,000 | |
| 2025-08-31 | 10-Q | -5,540,000 | 0.00 | 13,483,000 | -99,504,000 | |
| 2025-05-31 | 10-K | 3,745,000 | 0.00 | 18,047,000 | -96,042,000 | |
| 2025-02-28 | 10-Q | -4,758,000 | 0.00 | 21,191,000 | -92,979,000 | |
| 2024-11-30 | 10-Q | -4,768,000 | 0.00 | 24,877,000 | -89,390,000 | |
| 2024-08-31 | 10-Q | 19,227,000 | 0.02 | 28,021,000 | -85,210,000 | |
| 2024-05-31 | 10-K | -49,841,000 | -0.05 | 11,136,000 | -116,758,000 | |
| 2024-02-29 | 10-Q | -11,920,000 | -0.01 | 10,270,000 | -119,382,000 | |
| 2023-11-30 | 10-Q | -9,563,000 | -0.01 | 9,240,000 | -114,381,000 | |
| 2023-08-31 | 10-Q | -11,571,000 | -0.01 | 12,411,000 | -116,889,000 | |
| 2023-05-31 | 10-K | 0 | -79,824,000 | -0.10 | 11,292,000 | -109,501,000 |
| 2023-02-28 | 10-Q | -13,702,000 | -0.02 | 14,642,000 | -107,010,000 | |
| 2022-11-30 | 10-Q | -26,495,000 | -0.03 | 7,074,000 | -115,969,000 | |
| 2022-08-31 | 10-Q | -20,991,000 | -0.03 | 28,394,000 | -94,312,000 | |
| 2022-05-31 | 10-K | 266,000 | -210,820,000 | -0.31 | 29,185,000 | -94,398,000 |
| 2022-02-28 | 10-Q | 266,000 | -41,285,000 | -0.06 | 94,079,000 | -22,460,000 |
| 2022-02-28 | 10-K | -41,285,000 | -0.06 | |||
| 2021-11-30 | 10-Q | 225,000 | -40,077,000 | -0.06 | 103,699,000 | -12,696,000 |
| 2021-11-30 | 10-K | -40,077,000 | -0.06 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.